Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

373.83 +17.82 (+5.01%)
Streaming Delayed Price Updated: 3:20 PM EDT, May 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Argenx Se ADR

< Previous 1 2 3 Next >
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
From argenx SE
Via GlobeNewswire
argenx announces full exercise of underwriters’ option to purchase additional ADSs
From argenx SE
Via GlobeNewswire
argenx raises $1.1 billion in gross proceeds in a global offering
From argenx SE
Via GlobeNewswire
argenx announces launch of proposed global offering
From argenx SE
Via GlobeNewswire
argenx SE (NASDAQ: ARGX) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
From Zai Lab Limited
Via GlobeNewswire
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
From argenx SE
Via GlobeNewswire
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via GlobeNewswire
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx announces results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
argenx to Present at BofA Securities 2023 Health Care Conference
From argenx SE
Via GlobeNewswire
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
From argenx SE
Via GlobeNewswire
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
From argenx SE
Via GlobeNewswire
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
From argenx SE
Via GlobeNewswire
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
From argenx SE
Via GlobeNewswire
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
argenx Announces Planned Transition of Chief Operating Officer
From argenx SE
Via GlobeNewswire
argenx Appoints Steve Krognes to Board of Directors
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
From argenx SE
Via GlobeNewswire
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
From argenx SE
Via GlobeNewswire
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
From argenx SE
Via GlobeNewswire
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
From argenx SE
Via GlobeNewswire
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
argenx Appoints Ana Cespedes to Board of Directors
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.